Go Pro
→ The $15 Gold Fund That Pays Up to $1,152/Month (From Investors Alley) (Ad)tc pixel

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Compare
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
ANGLE plc stock logo
ANPCY
ANGLE
C$0.07
C$0.07
C$0.07
▼
C$2.39
N/AN/A11,295 shsN/A
Bullfrog AI Holdings, Inc. stock logo
BFRGW
Bullfrog AI
$0.09
-3.0%		$0.11
$0.08
▼
$0.60
N/AN/A12,043 shs5,801 shs
BG Medicine Inc. stock logo
BGMD
BG Medicine
$0.00
$0.00
▼
$0.00
N/A1.02N/AN/A
Epigenomics AG stock logo
EPGNY
Epigenomics
$2.39
$2.39
$2.01
▼
$2.39
N/AN/A100 shsN/A
(Almost) Everything You Need To Know About The EV Market Cover
(Almost) Everything You Need To Know About The EV Market

Looking to profit from the electric vehicle mega-trend? Click the link to see our list of which EV stocks show the most long-term potential.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
ANGLE plc stock logo
ANPCY
ANGLE
0.00%0.00%0.00%0.00%-85.62%
Bullfrog AI Holdings, Inc. stock logo
BFRGW
Bullfrog AI
-7.81%-19.07%-29.52%-32.77%-77.65%
BG Medicine Inc. stock logo
BGMD
BG Medicine
0.00%0.00%0.00%0.00%0.00%
Epigenomics AG stock logo
EPGNY
Epigenomics
0.00%0.00%0.00%0.00%0.00%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
ANGLE plc stock logo
ANPCY
ANGLE
C$0.07
C$0.07
C$0.07
▼
C$2.39
N/AN/A11,295 shsN/A
Bullfrog AI Holdings, Inc. stock logo
BFRGW
Bullfrog AI
$0.09
-3.0%		$0.11
$0.08
▼
$0.60
N/AN/A12,043 shs5,801 shs
BG Medicine Inc. stock logo
BGMD
BG Medicine
$0.00
$0.00
▼
$0.00
N/A1.02N/AN/A
Epigenomics AG stock logo
EPGNY
Epigenomics
$2.39
$2.39
$2.01
▼
$2.39
N/AN/A100 shsN/A
(Almost) Everything You Need To Know About The EV Market Cover
(Almost) Everything You Need To Know About The EV Market

Looking to profit from the electric vehicle mega-trend? Click the link to see our list of which EV stocks show the most long-term potential.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
ANGLE plc stock logo
ANPCY
ANGLE
0.00%0.00%0.00%0.00%-85.62%
Bullfrog AI Holdings, Inc. stock logo
BFRGW
Bullfrog AI
-7.81%-19.07%-29.52%-32.77%-77.65%
BG Medicine Inc. stock logo
BGMD
BG Medicine
0.00%0.00%0.00%0.00%0.00%
Epigenomics AG stock logo
EPGNY
Epigenomics
0.00%0.00%0.00%0.00%0.00%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
ANGLE plc stock logo
ANPCY
ANGLE
0.00
N/AN/AN/A
Bullfrog AI Holdings, Inc. stock logo
BFRGW
Bullfrog AI
0.00
N/AN/AN/A
BG Medicine Inc. stock logo
BGMD
BG Medicine
0.00
N/AN/AN/A
Epigenomics AG stock logo
EPGNY
Epigenomics
0.00
N/AN/AN/A
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
ANGLE plc stock logo
ANPCY
ANGLE
N/AN/AN/AN/AN/AN/A
Bullfrog AI Holdings, Inc. stock logo
BFRGW
Bullfrog AI
$298.80KN/AN/AN/AN/AN/A
BG Medicine Inc. stock logo
BGMD
BG Medicine
N/AN/AN/AN/AN/AN/A
Epigenomics AG stock logo
EPGNY
Epigenomics
N/AN/AN/AN/AN/AN/A
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
ANGLE plc stock logo
ANPCY
ANGLE
N/A-C$0.48N/AN/AN/AN/AN/AN/AN/A
Bullfrog AI Holdings, Inc. stock logo
BFRGW
Bullfrog AI
N/AN/AN/AN/AN/AN/AN/AN/AN/A
BG Medicine Inc. stock logo
BGMD
BG Medicine
N/AN/AN/AN/AN/AN/AN/AN/AN/A
Epigenomics AG stock logo
EPGNY
Epigenomics
N/A-$3.05N/AN/AN/AN/AN/AN/AN/A
CompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive Growth
ANGLE plc stock logo
ANPCY
ANGLE
N/AN/AN/AN/AN/A
Bullfrog AI Holdings, Inc. stock logo
BFRGW
Bullfrog AI
N/AN/AN/AN/AN/A
BG Medicine Inc. stock logo
BGMD
BG Medicine
N/AN/AN/AN/AN/A
Epigenomics AG stock logo
EPGNY
Epigenomics
N/AN/AN/AN/AN/A

Institutional Ownership

CompanyInstitutional Ownership
ANGLE plc stock logo
ANPCY
ANGLE
N/A
Bullfrog AI Holdings, Inc. stock logo
BFRGW
Bullfrog AI
N/A
BG Medicine Inc. stock logo
BGMD
BG Medicine
N/A
Epigenomics AG stock logo
EPGNY
Epigenomics
N/A

Insider Ownership

CompanyInsider Ownership
ANGLE plc stock logo
ANPCY
ANGLE
N/A
Bullfrog AI Holdings, Inc. stock logo
BFRGW
Bullfrog AI
N/A
BG Medicine Inc. stock logo
BGMD
BG Medicine
6.50%
Epigenomics AG stock logo
EPGNY
Epigenomics
N/A
CompanyEmployeesShares OutstandingFree FloatOptionable
ANGLE plc stock logo
ANPCY
ANGLE
173N/AN/ANot Optionable
Bullfrog AI Holdings, Inc. stock logo
BFRGW
Bullfrog AI
2N/AN/ANot Optionable
BG Medicine Inc. stock logo
BGMD
BG Medicine
5N/AN/ANot Optionable
Epigenomics AG stock logo
EPGNY
Epigenomics
32N/AN/ANot Optionable

Recent News About These Companies

Innovations in Epigenomics: Bridging Technology Development and Disease-Modifying Therapies
January 30, 2026  |  frontiersin.orgF
Insights in Genetics, Genomics and Epigenomics of Aging: 2025
January 31, 2025  |  frontiersin.orgF
Epigenomics Market Analysis, Technological Advancements, Key Applications, and Growth Forecasts from 2024 to 2032
October 18, 2024  |  taiwannews.com.twT
Epigenomics AG: Executive Board member Jens Ravens…
April 30, 2024  |  pharmiweb.comP
Epagny, Fribourg, Switzerland 10-Day Weather Forecaststar_ratehome
March 16, 2024  |  wunderground.comW
EQS-News: Epigenomics AG publishes financial results for fiscal year 2023
March 14, 2024  |  markets.businessinsider.comhttps://markets.businessinsider.com/news/stocks/eqs-news-epigenomics-ag-publishes-financial-results-for-fiscal-year-2023-1033162377
Epigenomics AG: Supervisory Board of Epigenomics AG appoints Hansjörg Plaggemars as member of the Executive Board
January 31, 2024  |  pharmiweb.comP
EQS-News: Epigenomics AG: Supervisory Board of Epigenomics AG appoints Hansjörg Plaggemars as member of the Executive Board
January 31, 2024  |  markets.businessinsider.comhttps://markets.businessinsider.com/news/stocks/eqs-news-epigenomics-ag-supervisory-board-of-epigenomics-ag-appoints-hansj-246-rg-plaggemars-as-member-of-the-executive-board-1033015408
Epigenomics AG: Resignation of Supervisory Board Member Dr Heikki Lanckriet (PhD)
January 26, 2024  |  pharmiweb.comP
Seminar Series
January 13, 2024  |  case.eduC
Epigenomics articles from across Nature Portfolio
December 5, 2023  |  nature.comN
SBC Job OpportunitiesJoin our team!
November 13, 2023  |  uwyo.eduU
EQS-Adhoc: Epigenomics AG: Closing of Agreement on the Acquisition of Almost All Assets and Adjustment of Guidance for 2023
October 10, 2023  |  markets.businessinsider.comhttps://markets.businessinsider.com/news/stocks/eqs-adhoc-epigenomics-ag-closing-of-agreement-on-the-acquisition-of-almost-all-assets-and-adjustment-of-guidance-for-2023-1032693757
EQS-News: Epigenomics AG Announces Closing of Agreement on the Acquisition of Almost All of the Company's Assets and Adjustment of Guidance for 2023
October 10, 2023  |  markets.businessinsider.comhttps://markets.businessinsider.com/news/stocks/eqs-news-epigenomics-ag-announces-closing-of-agreement-on-the-acquisition-of-almost-all-of-the-company-s-assets-and-adjustment-of-guidance-for-2023-1032693790
An epic advance in epigenomics: Automated CUT&RUN enables chromatin profiling for scaled research & drug discovery applications
September 28, 2023  |  labroots.comL
Cardio Diagnostics Publishes Novel and Scalable Pathways to Enhance Global Coronary Heart Disease Care through Precision Epigenetics in Epigenomics
September 20, 2023  |  finance.yahoo.comhttps://finance.yahoo.com/news/cardio-diagnostics-publishes-novel-scalable-130100640.html
Colon Ischemia: Don't Miss This
September 19, 2023  |  medscape.comM
New Day Diagnostics Announces Approval of Purchase Agreement by Epigenomics' AG Extraordinary General Meeting
September 14, 2023  |  benzinga.comhttps://www.benzinga.com/pressreleases/23/09/b34585391/new-day-diagnostics-announces-approval-of-purchase-agreement-by-epigenomics-ag-extraordinary-gener
EQS-News: Epigenomics AG publishes financial results for the first six months 2023
August 10, 2023  |  markets.businessinsider.comhttps://markets.businessinsider.com/news/stocks/eqs-news-epigenomics-ag-publishes-financial-results-for-the-first-six-months-2023-1032538927
Epigenomics AG: Capital reduction planned at a ratio of 5 : 1
August 2, 2023  |  pharmiweb.comP

Media Sentiment Over Time

ANGLE stock logo

ANGLE OTCMKTS:ANPCY

C$0.07 0.00 (0.00%)
As of 09/10/2026

ANGLE plc, a medical diagnostic company, engages in developing cancer diagnostics products in Europe, North America, and the United Kingdom. The company develops and commercializes Parsortix cell separation system, which captures and harvests circulating tumor cells in metastatic breast cancer patient blood; and HyCEAD. ANGLE plc has a partnership agreement with Bio View Ltd to develop a liquid biopsy circulating tumor cell HER2 assay for breast cancer. The company was founded in 1994 and is based in Guildford, the United Kingdom.

Bullfrog AI stock logo

Bullfrog AI NASDAQ:BFRGW

$0.09 0.00 (-3.00%)
As of 09/11/2026 03:57 PM Eastern
This is a fair market value price provided by Massive. Learn more.

BullFrog AI Holdings, Inc., through its subsidiaries, operates as a digital biopharmaceutical company that focuses on artificial intelligence and machine learning (AI/ML) driven analysis of data sets in medicine and healthcare in the United States. It offers bfLEAP, an AI/ML platform for the analysis of preclinical and/or clinical data. The company also has licensing agreements with George Washington University for rights to use siRNA targeting Beta2-spectrin in the treatment of human diseases, including hepatocellular carcinoma, obesity, non-alcoholic fatty liver disease, and non-alcoholic steatohepatitis; and Johns Hopkins University for the use of a formulation of Mebendazole for the treatment of human cancer or neoplastic disease. The company was founded in 2017 and is based in Gaithersburg, Maryland.

BG Medicine stock logo

BG Medicine OTCMKTS:BGMD

BG Medicine, Inc. engages in the development and commercialization of diagnostic products used to guide the patients suffering from heart failure and related disorders in the United States. The company offers BGM Galectin-3 Test, an in vitro diagnostic device that measures galectin-3 in serum or plasma by enzyme linked immunosorbent assay on a microtiter plate platform; and CardioSCORE Test, a multi-analyte biomarker-based blood test used for the assessment of near-term risk of atherothrombotic cardiovascular events, such as heart attack and ischemic stroke. It has license, development, and commercialization agreements with Abbott Laboratories, bioMérieux SA, Siemens Healthcare Diagnostics Inc., and Alere Inc. for the automated instrument versions of galectin-3 test; and a strategic collaboration with Abbott Laboratories to develop and commercialize galectin-3 assay kits, and related control kits and calibrators. The company was formerly known as Beyond Genomics, Inc. and changed its name to BG Medicine, Inc. in October 2004. BG Medicine, Inc. was founded in 2000 and is headquartered in Waltham, Massachusetts.

Epigenomics stock logo

Epigenomics OTCMKTS:EPGNY

$2.39 0.00 (0.00%)
As of 04/6/2023

Epigenomics AG, a molecular diagnostics company, focuses on liquid biopsy for the early detection of cancer. Its lead product is Epi proColon, a blood-based test for the early detection of colorectal cancer in the United States, Europe, and China. The company's products also include hepatocellular carcinoma blood test; Epi proColon, a liquid biopsy test for detection of colorectal cancer; and Epi BiSKit, a pre-analytical tool, which provides a set of reagents for the preparation of bisulfite-converted DNA. Its research and development activities identify suitable biomarkers in human tissue and developing and patenting the corresponding in vitro diagnostic blood tests. Epigenomics AG was founded in 1998 and is headquartered in Berlin, Germany.

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

Stock Lists
Low Priced Stocks
Stocks By Exchange
Latest Stock Ideas